See more : UBE Corporation (UBEOY) Income Statement Analysis – Financial Results
Complete financial analysis of FibroBiologics, Inc. Common Stock (FBLG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of FibroBiologics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bass Oil Limited (BAS.AX) Income Statement Analysis – Financial Results
- COVER Corporation (5253.T) Income Statement Analysis – Financial Results
- Samsonite International S.A. (SMSOF) Income Statement Analysis – Financial Results
- Japan Exchange Group, Inc. (JPXGY) Income Statement Analysis – Financial Results
- Danske Invest Euro Investment Grade – Obligationer (DKIEIGO.CO) Income Statement Analysis – Financial Results
FibroBiologics, Inc. Common Stock (FBLG)
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 437.00K | 94.00K | 0.00 | 0.00 |
| Gross Profit | -437.00K | -94.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.37M | 1.15M | 521.00K | 669.00K |
| General & Administrative | 5.84M | 3.32M | 1.06M | 500.00K |
| Selling & Marketing | 685.00K | -94.00K | 0.00 | 0.00 |
| SG&A | 6.52M | 3.23M | 1.06M | 500.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.89M | 4.37M | 1.58M | 1.17M |
| Cost & Expenses | 8.89M | 4.47M | 1.58M | 1.17M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 147.00K | 654.00K | 4.00K | 0.00 |
| Depreciation & Amortization | 437.00K | 94.00K | 0.00 | 1.17M |
| EBITDA | -15.90M | -4.37M | -1.58M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.89M | -4.47M | -1.58M | -1.17M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -7.60M | -654.00K | -4.00K | 0.00 |
| Income Before Tax | -16.49M | -5.12M | -1.58M | -1.17M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -16.49M | -5.12M | -1.58M | -1.17M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.59 | -0.16 | -0.05 | -0.13 |
| EPS Diluted | -0.68 | -0.16 | -0.05 | -0.13 |
| Weighted Avg Shares Out | 32.49M | 32.49M | 32.49M | 8.75M |
| Weighted Avg Shares Out (Dil) | 28.23M | 32.49M | 32.49M | 8.75M |
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived...
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived...
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the second quarter of 2025
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived...
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived...
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading global drug discovery, development, testing, and manufacturing solutions provider established a master services agreement to develop and manufacture FibroBiologics' therapeutic...
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and...
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived...
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs
FibroBiologics Engages Southern Star Research as CRO in Australia
Southern Star Research will provide CRO services for FibroBiologics in Australia Southern Star Research will provide CRO services for FibroBiologics in Australia
Source: https://incomestatements.info
Category: Stock Reports